2024-05-31 12:04:07 ET
Summary
- Coherus BioSciences, Inc. is relying on revenues from existing drugs and its developmental pipeline after selling off a major source of revenue in Cimerli.
- CHS-114, an anti-CCR8 antibody being developed by CHRS, is set to produce data at the ASCO 2024 Annual Meeting.
- Coherus BioSciences refers to Yusimry (a biosimilar Humira) as a non-core product, and could look to sell the drug, although revenues are growing.
...
Read the full article on Seeking Alpha
For further details see:
Coherus BioSciences: CHS-114 Comes Into View At ASCO, Drug Launches Underway